Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara

Journal of General Virology

Volumn 87, Issue 5, 2006, Pages 1145-1155

  Ludwig, Holger ^a   Suezer, Yasemin ^a   Waibler, Zoe ^a   Kalinke, Ulrich ^a   Schnierle, Barbara S ^a   Sutter, Gerd ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; DOUBLE STRANDED RNA; INITIATION FACTOR 2ALPHA; PROTEIN KINASE; RIBONUCLEASE A; RIBONUCLEASE L; RIBONUCLEASE T1; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; HELA CELL; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIFE CYCLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RNA BINDING; RNA DEGRADATION; RNA SYNTHESIS; RNA TRANSLATION; TRANSLATION REGULATION; VACCINIA VIRUS; VIRUS TRANSCRIPTION; WESTERN BLOTTING;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; CELLS, CULTURED; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MICE; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; RNA, DOUBLE-STRANDED; RNA, MESSENGER; RNA, VIRAL; RNA-BINDING PROTEINS; SPECIES SPECIFICITY; TRANSCRIPTION FACTORS; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

ANKARA; EUKARYOTA; VACCINIA VIRUS;

EID: 33646134619     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81623-0     Document Type: Article

References (76)

1. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
2. Baglioni, C., De Benedetti, A. & Williams, G. J. (1984). Cleavage of nascent reovirus mRNA by localized activation of the 2′-5′-oligoadenylate-dependent endoribonuclease. J Virol 52, 865-871.
3. Baldick, C. J., Jr & Moss, B. (1993). Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes. J Virol 67, 3515-3527.
4. Beattie, E., Tartaglia, J. & Paoletti, E. (1991). Vaccinia virus-encoded eIF-2α homolog abrogates the antiviral effect of interferon. Virology 183, 419-422.
5. - mutant viruses. Virology 210, 254-263.
6. Beattie, E., Kauffman, E. B., Martinez, H., Perkus, M. E., Jacobs, B. L., Paoletti, E. & Tartaglia, J. (1996). Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes 12, 89-94.
7. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167.
8. Boone, R. F., Parr, R. P. & Moss, B. (1979). Intermolecular duplexes formed from polyadenylylated vaccinia virus RNA. J Virol 30, 365-374.
9. Born, T. L., Morrison, L. A., Esteban, D. J., VandenBos, T., Thebeau, L. G., Chen, N., Spriggs, M. K., Sims, J. E. & Buller, R. M. L. (2000). A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol 164, 3246-3254.
10. Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A. & Fusenig, N. E. (1988). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106, 761-771.
11. Brandt, T. A. & Jacobs, B. L. (2001). Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75, 850-856.
12. Brandt, T., Heck, M. C., Vijaysri, S., Jentarra, G. M., Cameron, J. M. & Jacobs, B. L. (2005). The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 333, 263-270.
13. Broyles, S. S. (2003). Vaccinia virus transcription. J Gen Virol 84, 2293-2303.
14. Carroll, M. W. & Moss, B. (1997). Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198-211.
15. Carroll, K., Elroy-Stein, O., Moss, B. & Jagus, R. (1993). Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2α-specific protein kinase. J Biol Chem 268, 12837-12842.
16. Chang, H.-W. & Jacobs, B. L. (1993). Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 194, 537-547.
17. Chang, H.-W., Watson, J. C. & Jacobs, B. L. (1992). The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A 89, 4825-4829.
18. Chang, H.-W., Uribe, L. H. & Jacobs, B. L. (1995). Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J Virol 69, 6605-6608.
19. Clemens, M. J. & Elia, A. (1997). The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17, 503-524.
20. Colby, C. & Duesberg, P. H. (1969). Double-stranded RNA in vaccinia virus infected cells. Nature 222, 940-944.
21. Colby, C., Jurale, C. & Kates, J. R. (1971). Mechanism of synthesis of vaccinia virus double-stranded ribonucleic acid in vivo and in vitro. J Virol 7, 71-76.
22. Condit, R. C. & Niles, E. G. (2002). Regulation of viral transcription elongation and termination during vaccinia virus infection. Biochim Biophys Acta 1577, 325-336.
23. Cooper, J. A., Wittek, R. & Moss, B. (1981). Extension of the transcriptional and translational map of the left end of the vaccinia virus genome to 21 kilobase pairs. J Virol 39, 733-745.
24. Czerny, C.-P., Johann, S., Hölzle, L. & Meyer, H. (1994). Epitope detection in the envelope of intracellular naked orthopox viruses and identification of encoding genes. Virology 200, 764-777.
25. Davies, M. V., Elroy-Stein, O., Jagus, R., Moss, B. & Kaufman, R. J. (1992). The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J Virol 66, 1943-1950.
26. Díaz-Guerra, M., Rivas, C. & Esteban, M. (1997). Inducible expression of the 2-5A synthetase/RNase L system results in inhibition of vaccinia virus replication. Virology 227, 220-228.
27. Drexler, I., Heller, K., Wahren, B., Erfle, V. & Sutter, G. (1998). Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79, 347-352.
28. Drexler, I., Staib, C. & Sutter, G. (2004). Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15, 506-512.
29. Floyd-Smith, G., Slattery, E. & Lengyel, P. (1981). Interferon action: RNA cleavage pattern of a (2′-5′)oligoadenylate-dependent endonuclease. Science 212, 1030-1032.
30. García, M. A., Guerra, S., Gil, J., Jimenez, V. & Esteban, M. (2002). Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 21, 8379-8387.
31. Goodbourn, S., Didcock, L. & Randall, R. E. (2000). Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81, 2341-2364.
32. Herbert, A., Alfken, J., Kim, Y.-G., Mian, I. S., Nishikura, K. & Rich, A. (1997). A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Proc Natl Acad Sci U S A 94, 8421-8426.
33. Ho, C. K. & Shuman, S. (1996). Physical and functional characterization of the double-stranded RNA binding protein encoded by the vaccinia virus E3 gene. Virology 217, 272-284.
34. Hornemann, S., Harlin, O., Staib, C., Kisling, S., Erfle, V., Kaspers, B., Häcker, G. & Sutter, G. (2003). Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol 77, 8394-8407.
35. Jagus, R. & Gray, M. M. (1994). Proteins that interact with PKR. Biochimie 76, 779-791.
36. Kahmann, J. D., Wecking, D. A., Putter, V., Lowenhaupt, K., Kim, Y.-G., Schmieder, P., Oschkinat, H., Rich, A. & Schade, M. (2004). The solution structure of the N-terminal domain of E3L shows a tyrosine conformation that may explain its reduced affinity to Z-DNA in vitro. Proc Natl Acad Sci U S A 101, 2712-2717.
37. Kato, H., Sato, S., Yoneyama, M. & 8 other authors (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28.
38. Keck, J. G., Baldick, C. J., Jr & Moss, B. (1990). Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell 61, 801-809.
39. Keck, J. G., Kovacs, G. R. & Moss, B. (1993). Overexpression, purification, and late transcription factor activity of the 17-kilodalton protein encoded by the vaccinia virus A1L gene. J Virol 67, 5740-5748.
40. Kerr, I. M. & Brown, R. E. (1978). pppA2′p5′A2′p5′A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci U S A 75, 256-260.
41. Kim, Y.-G., Muralinath, M., Brandt, T., Pearcy, M., Hauns, K., Lowenhaupt, K., Jacobs, B. L. & Rich, A. (2003). A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci U S A 100, 6974-6979.
42. Kim, Y.-G., Lowenhaupt, K., Oh, D.-B., Kim, K. K. & Rich, A. (2004). Evidence that vaccinia virulence factor E3L binds to Z-DNA in vivo: implications for development of a therapy for poxvirus infection. Proc Natl Acad Sci U S A 101, 1514-1518.
43. Kumar, R., Choubey, D., Lengyel, P. & Sen, G. C. (1988). Studies on the role of the 2′-5′-oligoadenylate synthetase-RNase L pathway in beta interferon-mediated inhibition of encephalomyocarditis virus replication. J Virol 62, 3175-3181.
44. Langland, J. O. & Jacobs, B. L. (2002). The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology 299, 133-141.
45. Langland, J. O. & Jacobs, B. L. (2004). Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. Virology 324, 419-429.
46. Leitner, W. W., Hwang, L. N., deVeer, M. J., Zhou, A., Silverman, R. H., Williams, B. R. G., Dubensky, T. W., Ying, H. & Restifo, N. P. (2003). Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9, 33-39.
47. Li, X.-L., Blackford, J. A. & Hassel, B. A. (1998). RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol 72, 2752-2759.
48. Ludwig, H., Mages, J., Staib, C., Lehmann, M. H., Lang, R. & Sutter, G. (2005). Role of viral factor E3L in modified vaccinia virus Ankara infection of human HeLa cells: regulation of the virus life cycle and identification of differentially expressed host genes. J Virol 79, 2584-2596.
49. Mahr, A. & Roberts, B. E. (1984). Arrangement of late RNAs transcribed from a 7.1-kilobase EcoRI vaccinia virus DNA fragment. J Virol 49, 510-520.
50. Mayr, A., Hochstein-Mintzel, V. & Stickl, H. (1975). Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3, 6-14 (in German).
51. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
52. Moss, B. (1990). Regulation of vaccinia virus transcription. Annu Rev Biochem 59, 661-688.
53. Moss, B. & Shisler, J. L. (2001). Immunology 101 at poxvirus U: immune evasion genes. Semin Immunol 13, 59-66.
54. Patterson, J. B. & Samuel, C. E. (1995). Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 15, 5376-5388.
55. Rivas, C., Gil, J., Mělková, Z., Esteban, M. & Díaz-Guerra, M. (1998). Vaccinia virus E3L protein is an inhibitor of the interferon (IFN)-induced 2-5A synthetase enzyme. Virology 243, 406-414.
56. r envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers. J Virol 61, 395-404.
57. Sanz, P. & Moss, B. (1999). Identification of a transcription factor, encoded by two vaccinia virus early genes, that regulates the intermediate stage of viral gene expression. Proc Natl Acad Sci U S A 96, 2692-2697.
58. Schulz, O., Diebold, S. S., Chen, M. & 7 other authors (2005). Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433, 887-892.
59. Shors, T., Kibler, K. V., Perkins, K. B., Seidler-Wulff, R., Banaszak, M. P. & Jacobs, B. L. (1997). Complementation of vaccinia virus deleted of the E3L gene by mutants of E3L. Virology 239, 269-276.
60. Shors, S. T., Beattie, E., Paoletti, E., Tartaglia, J. & Jacobs, B. L. (1998). Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res 18, 721-729.
61. Silverman, R. H., Cayley, P. J., Knight, M., Gilbert, C. S. & Kerr, I. M. (1982). Control of the ppp(a2′p)nA system in HeLa cells. Effects of interferon and virus infection. Eur J Biochem 124, 131-138.
62. nA activity in interferon-treated encephalomyocarditis virus-infected cells. J Virol 46, 1051-1055.
63. Smith, V. P., Bryant, N. A. & Alcamí, A. (2000). Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol 81, 1223-1230.
64. Smith, E. J., Marié, I., Prakash, A., García-Sastre, A. & Levy, D. E. (2001). IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or IκB kinase but is blocked by vaccinia virus E3L protein. J Biol Chem 276, 8951-8957.
65. + T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 86, 1997-2006.
66. Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H. & Schreiber, R. D. (1998). How cells respond to interferons. Annu Rev Biochem 67, 227-264.
67. Sutter, G. & Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89, 10847-10851.
68. Sutter, G. & Staib, C. (2003). Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3, 263-271.
69. Thomis, D. C. & Samuel, C. E. (1993). Mechanism of interferon action: evidence for intermolecular autophosphorylation and auto-activation of the interferon-induced, RNA-dependent protein kinase PKR. J Virol 67, 7695-7700.
70. Varich, N. L., Sychova, I. V., Kaverin, N. V., Antonova, T. P. & Chernos, V. I. (1979). Transcription of both DNA strands of vaccinia virus genome in vivo. Virology 96, 412-430.
71. Vos, J. C. & Stunnenberg, H. G. (1988). Derepression of a novel class of vaccinia virus genes upon DNA replication. EMBO J 7, 3487-3492.
72. Watson, J. C., Chang, H.-W. & Jacobs, B. L. (1991). Characterization of a vaccinia virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded RNA-dependent protein kinase. Virology 185, 206-216.
73. nA) in interferon-treated cells. Nucleic Acids Res 9, 1571-1581.
74. Xiang, Y., Condit, R. C., Vijaysri, S., Jacobs, B., Williams, B. R. G. & Silverman, R. H. (2002). Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 76, 5251-5259.
75. Yang, Y.-L., Reis, L. F. L., Pavlovic, J., Aguzzi, A., Schafer, R., Kumar, A., Williams, B. R. G., Aguet, M. & Weissmann, C. (1995). Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 14, 6095-6106.
76. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S. & Fujita, T. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5, 730-737.